Disparities Emerge in Nirsevimab Uptake for RSV Prevention

Key Takeaways Highlight Unequal Access to Crucial Antibody

A recent study published in Pediatrics has shed light on significant disparities in the uptake of nirsevimab, a monoclonal antibody designed to protect infants from severe respiratory syncytial virus (RSV) disease. While nirsevimab offers a vital layer of defense, the research indicates that access and administration are not uniform across all eligible infants, with sociodemographic factors playing a crucial role.

The study,which analyzed data from a single care network,found that 35% of eligible children received nirsevimab. However, this figure masked considerable variation, with uptake ranging from a low of 20% to a high of 65% across different practices. Among those who received the antibody, a majority (53.1%) were White, and a larger proportion (64.4%) had private insurance, suggesting potential barriers for other groups.

Factors Influencing Nirsevimab Receipt

The research identified several key factors associated with the likelihood of an infant receiving nirsevimab. Older infants, for each additional month of age, had reduced odds of receiving the protection (adjusted odds ratio [aOR] 0.60; 95% CI, 0.58-0.62). Conversely, infants with lower birth weight were more likely to receive nirsevimab (aOR, 1.43; 95% CI, 1.13-1.82),potentially reflecting higher-risk infants being prioritized or more closely monitored.

More concerning are the findings related to racial and socioeconomic disparities. Black infants were significantly less likely to receive nirsevimab compared to their White counterparts (aOR, 0.53; 95% CI, 0.43-0.65). Similarly, infants with public insurance had lower odds of receiving the antibody than those with private insurance (aOR, 0.79; 95% CI, 0.67-0.92). The study also noted that children living in areas with very low opportunity had a 30% lower chance of receiving nirsevimab compared to those in very high-opportunity areas (aOR, 0.70; 95% CI, 0.54-0.91).

Even among infants who were fully vaccinated against common childhood illnesses like diphtheria, Haemophilus influenzae type B, poliovirus, Streptococcus pneumoniae, tetanus, and pertussis, only 38.7% received nirsevimab,indicating that general vaccination status alone did not guarantee nirsevimab administration.

Implications for Equitable Protection

The study’s authors emphasize the critical need to address these identified disparities. “The identification of sociodemographic factors associated with receipt of nirsevimab emphasizes the importance of examining the drivers of these disparities to inform interventions designed to ensure more equitable uptake so that all children are protected from RSV,” they concluded. This sentiment underscores the ethical imperative to ensure that life-saving medical advancements are accessible to all infants, regardless of their background or socioeconomic status.

Understanding the Study’s Scope and Limitations

The study included infants who were at least 3.5 months old at the start of the observation period, with a demographic breakdown of 49% girls and 51.3% White. All participants had at least one primary care visit within 14 days of birth and another after reaching 8 months of age or after the RSV season concluded.

Though, the researchers acknowledge several limitations.The data was drawn from practices within a single care network, which may limit the generalizability of the findings to broader populations. Furthermore, the study focused on infants entering their first RSV season, preventing an analysis of nirsevimab uptake among high-risk infants entering their second season. As a retrospective study relying on electronic health records, it coudl not capture crucial qualitative data such as family preferences, knowledge about nirsevimab, or the nuances of family-clinician interactions during vaccination discussions.

Expert Insights and Future Directions

The findings from this study are crucial for public health initiatives and healthcare providers aiming to maximize the protective benefits of nirsevimab. Understanding the barriers to equitable access is the first step toward developing targeted interventions.These could include enhanced patient education, streamlined prescription processes, and proactive outreach to underserved communities.